Insmed Incorporated (NASDAQ:INSM) CFO Sells $2,296,751.00 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 28,390 shares of the firm’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,296,751.00. Following the sale, the chief financial officer now owns 155,506 shares in the company, valued at $12,580,435.40. This trade represents a 15.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total value of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Stock Down 1.0 %

Shares of NASDAQ:INSM traded down $0.83 during trading on Friday, reaching $79.95. 1,690,520 shares of the company traded hands, compared to its average volume of 1,955,787. The firm has a fifty day simple moving average of $72.79 and a 200 day simple moving average of $73.10. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $82.04. The firm has a market cap of $14.30 billion, a P/E ratio of -14.41 and a beta of 1.11.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the third quarter worth approximately $30,000. GAMMA Investing LLC raised its holdings in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the last quarter. Spire Wealth Management bought a new position in Insmed in the 4th quarter worth approximately $47,000. Finally, Exchange Traded Concepts LLC raised its holdings in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Truist Financial reaffirmed a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. upped their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday. Guggenheim upped their price objective on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Finally, Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.